Lead Partnered Asset JNJ-5120/PIPE-307 Misses Phase 2 Primary Endpoint in Major Depressive Disorder

summarizeSummary

Contineum's partnered lead asset JNJ-5120/PIPE-307 failed its Phase 2 primary efficacy endpoint in major depressive disorder. The drug was well-tolerated, and J&J is still reviewing exploratory data, but the miss is a major setback for the program's prospects.

check_boxKey Events · Product Development and Regulatory · CTNM

• Phase 2 Primary Endpoint Miss

  The MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder did not achieve its primary efficacy endpoint — improvement in MADRS total score at Day 5 versus placebo.

• Safety Profile Clean

  JNJ-5120/PIPE-307 was well-tolerated with no new safety signals, which may support continued evaluation despite the efficacy miss.

• J&J Reviewing Exploratory Data

  Johnson & Johnson continues to analyze prespecified exploratory endpoints and assess the totality of findings before deciding next steps for the program.

• Partnership Risk Rises

  The failure increases the risk that J&J deprioritizes or terminates the global license and development agreement, removing a key external value driver for Contineum.

auto_awesomeAnalysis · CTNM · Life Sciences

The MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 — the lead asset partnered with Johnson & Johnson — missed its primary efficacy endpoint on the MADRS depression scale at Day 5. For a clinical-stage company heavily dependent on this program, the setback is thesis-altering. The drug was well-tolerated with no new safety signals, and J&J is still analyzing exploratory endpoints, so the program is not formally dead. However, the failure removes the near-term value driver for the partnership and raises the risk that J&J could deprioritize or terminate development. Contineum's own internal pipeline (PIPE-791) now carries more of the valuation weight.